Subscribe To

Price Alert Latest News Economic Calendar News

ANGO / AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023

LATHAM, N.Y.--( BUSINESS WIRE )--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open on Thursday, January 5, 2023. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. Read More

Demo Live Account See Partner Details

Content Topics

Angiodynamics

Report

Fiscal

2023

Second

Quarter

Financial

Results

January

Stock

ANGO

Posted: Dec 15 2022, 16:01

Author Name: Business Wire

ANGO News

By Zacks Investment Research
October 6, 2023

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

By Zacks Investment Research
October 5, 2023

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.

By The Motley Fool
October 4, 2023

Why Angiodynamics Stock Sank Today

The medical device and technology specialist unveiled its latest set of quarterly results. Its bottom line was in the red and only marginally beat est

By Zacks Investment Research
October 4, 2023

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss o

By Seeking Alpha
September 17, 2023

AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity Picture

AngioDynamics, Inc. posted mixed results in its FY'23 reports, with strong growth in its Med Tech division. The company's focus going forward will be

By Zacks Investment Research
August 17, 2023

AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know

AngioDynamics (ANGO) closed at $8.58 in the latest trading session, marking no change from the prior day.

By Zacks Investment Research
August 16, 2023

AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment

The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimi

By Zacks Investment Research
July 12, 2023

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

AngioDynamics (ANGO) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.03 per share. This compares to ea

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.